Roche account plan
Personalized healthcare and innovation
At a glance
Roche is a Basel-based pharmaceuticals and diagnostics group with CHF 61.5 billion of 2025 sales and 112,774 employees.
Roche is a Basel-based healthcare group with two divisions, Pharmaceuticals and Diagnostics, focused on oncology, neurology and cardiovascular-metabolic diseases, among other areas. In 2025 Group sales rose 7% at constant exchange rates (CER) to CHF 61,516 million, core operating profit rose 13% to CHF 21,833 million and IFRS net income rose 58% to CHF 13.8 billion. The group treated more than 39 million patients with its medicines and delivered 31 billion diagnostic tests in 2025. It employed 112,774 people (headcount), 53,638 of them in Europe and 27,594 in North America. Severin Schwan chairs the board and Thomas Schinecker is CEO.
Business units
Pharmaceuticals
CHF 47,669 million 2025 sales, about 78% of Group salesPrescription medicines across oncology/haematology, neurology, immunology, ophthalmology and cardiovascular/renal/metabolism, including Chugai in Japan. Top sellers are Ocrevus (CHF 7,010 million), Hemlibra, Vabysmo, Tecentriq and Xolair; sales grew 9% CER in 2025 and 6% CER in H1 2026. Led by Teresa Graham, CEO Roche Pharmaceuticals.
Diagnostics - Core Lab
CHF 7,614 million 2025 sales, about 55% of DiagnosticsCentral-lab immunoassays, clinical chemistry and custom biotech, with more than 6,700 cobas pro and 3,400 cobas pure units placed. Sales were flat in 2025 as China declines offset growth in EMEA and North America; H1 2026 grew 4%.
Diagnostics - Molecular Lab
CHF 2,527 million 2025 salesPathogen detection, blood donor screening, sexual health, genomics and Foundation Medicine; sales grew 4% in 2025. The SBX sequencing technology led to the Xelios 1 sequencer launched on 29 June 2026.
Diagnostics - Near Patient Care
CHF 1,983 million 2025 salesDecentralised testing in emergency rooms, GP practices and at home, plus diabetes management such as the Accu-Chek SmartGuide CGM. Sales fell 3% in 2025 and 5% in H1 2026 on lower respiratory testing.
Diagnostics - Pathology Lab
CHF 1,723 million 2025 salesTissue and companion diagnostics; sales grew 14% in 2025 and 11% in H1 2026. The PathAI acquisition adds AI-powered digital pathology. The Diagnostics division is led by Matt Sause.
Strategic priorities
- 20 transformative medicines by 2029
- The pharma strategy aims to bring 20 transformative medicines to patients by 2029; ten had been delivered by end-2025, and 19 medicines could launch by the end of the decade.
- R&D Excellence and pipeline
- Ten molecules entered phase III in 2025, a record, including trontinemab (Alzheimer's) and zosurabalpin; the pipeline holds 66 new molecular entities, with 66% of the late-stage portfolio having best-in-disease potential against an 80% target.
- Obesity and cardiovascular-metabolic
- CT-388 (enicepatide) phase III started in 2026, petrelintide with Zealand Pharma received a phase III go, and the 89bio acquisition adds pegozafermin for MASH.
- Diagnostics growth platforms
- Predictive CGM, fully automated mass spectrometry, SBX sequencing (a potential CHF 1 billion-plus product), blood-based Alzheimer's tests and AI algorithms; target of mid single digit growth in 2026 and mid-to-high single digit in 2027.
- Margin and AI in development
- Roche intends to expand Group margin in 2026 and keep it at least stable thereafter, with R&D broadly flat and AI used across the development process.
Latest results
In H1 2026 Group sales were CHF 30,364 million, up 6% at CER but down 2% in Swiss francs, as the strong franc cut 8 points from sales. Core operating profit rose 10% CER to CHF 11,856 million (margin 39.0%) and core EPS 9% to CHF 10.85, while IFRS net income fell 6% to CHF 7,325 million after CHF 1.0 billion of impairments. Pharmaceuticals sales were CHF 23,629 million (+6%), led by Xolair, Hemlibra, Ocrevus and Phesgo; Diagnostics sales were CHF 6,735 million (+3%), with China down 15%. Free cash flow was CHF 4,197 million and net debt rose to CHF 22.1 billion after CHF 8.3 billion of dividends. Guidance for 2026 was confirmed: mid single digit sales growth and high single digit core EPS growth at CER, with a higher dividend.
Investments and deals
- USD 50 billion US investment
- USD 50 billion over five years in US R&D and manufacturing, including USD 2 billion in CVRM manufacturing at Holly Springs, CGM manufacturing in Indianapolis and a Boston research hub, linked to a three-year tariff exemption.
- Building 12 in Basel
- A CHF 500 million R&D centre whose construction began in 2025.
- 2026 acquisitions
- SAGA Dx for USD 408 million (molecular residual disease), PathAI for about USD 750 million plus up to USD 300 million (AI pathology), and USD 700 million upfront for Nurix's BTK degrader.
- Partnerships
- 51 new partnerships in 2025, including the Zealand Pharma petrelintide deal and the agreement to acquire 89bio.
- Restructuring
- Restructuring costs of CHF 765 million in H1 2026 for R&D optimisation, business process transformation and organisational effectiveness.
Challenges and risks
- Biosimilar erosion
- Products with expired patents fell CHF 0.7 billion in 2025; the first US Xolair biosimilars are expected from H2 2026 and Perjeta biosimilars from 2027 in Europe.
- China pricing reforms
- Reforms cut Diagnostics sales in Asia-Pacific by 12% in 2025 and China Diagnostics sales by 15% in H1 2026.
- Currency
- Swiss franc strength cut 8 points from H1 2026 sales and 11 points from core operating profit.
- Tariffs and costs
- US tariffs raised Diagnostics cost of sales, which absorbed about 43 million of tariffs in H1 2026.
- Competition in key brands
- Competition in anti-CD20 slows Ocrevus, Tecentriq faces competition in Europe and the US branded eye-care market contraction weighs on Vabysmo.
What leadership says
“We always said we will deliver, and we delivered”
“we do not expect a patent cliff”
“usually we were not the highest bidder when we won the deals”
“a company reveals its true strength in a challenging environment”
Where a supplier can help
- US manufacturing and R&D build-out
- The USD 50 billion US programme, including Holly Springs and Indianapolis plants, creates demand for construction, equipment, automation and supply-chain partners.
- Clinical trial capacity
- Ten new phase III programmes and R&D efficiencies reallocated to phase III point to CRO, site and trial technology suppliers.
- AI in development and pathology
- AI used throughout development and the PathAI acquisition open room for data, AI and digital pathology integration partners.
- Cost and margin programmes
- Restructuring for business process transformation and the goal to expand margin fit process automation and efficiency services.
- Diagnostics launches
- SBX sequencing, mass spectrometry and CGM launches need manufacturing, distribution and lab-workflow partners to scale.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Roche?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Roche Annual Report 2025
- Roche is a Basel-based healthcare group with two divisions, Pharmaceuticals and Diagnostics; 2025 Group sales rose 7% at constant exchange rates (CER) to CHF 61.5 billion (61,516 million), 2% in CHF.
- Pharmaceuticals sales grew 9% (CER) to CHF 47.7 billion; Diagnostics grew 2% to CHF 13.8 billion, held back by healthcare pricing reforms in China.
- Core operating profit rose 13% to CHF 21.8 billion and core EPS 11%; IFRS net income rose 58% to CHF 13.8 billion; proposed dividend CHF 9.80, the 39th consecutive increase.
- Top five growth drivers (Phesgo, Xolair, Ocrevus, Hemlibra, Vabysmo) sold CHF 21.4 billion, up CHF 3.2 billion; products with expired patents fell a combined CHF 0.7 billion.
- Record pipeline year: ten new molecules entered phase III (Alzheimer's, Parkinson's, MS, obesity, hypertension, haemophilia A, cancers, the antibiotic zosurabalpin); 66 new molecular entities in the pipeline; 21 major pharma approvals.
- Pharma strategy: 20 transformative medicines by 2029 across five therapeutic areas; ten delivered by end-2025, 66% of the late-stage portfolio with best-in-disease potential, up to 19 new molecular entities that could launch by 2030.
- Business development: 51 new partnerships in 2025, including the Zealand Pharma petrelintide (obesity) deal and the agreement to acquire 89bio (MASH).
- USD 50 billion investment programme in the US over five years to strengthen local R&D and manufacturing and reduce exposure to supply chain risks and tariffs; CHF 500 million Building 12 R&D centre in Basel.
- 2026 outlook: Group sales up mid single digit (CER), core EPS up high single digit (CER), further dividend increase in CHF.
- 112,774 employees (headcount); Chairman Severin Schwan, CEO Thomas Schinecker.
- Roche Half-Year Report 2026
- H1 2026 Group sales CHF 30,364 million, +6% at CER (–2% in CHF, +8% in USD); the strong Swiss franc cut 8 points from sales and 11 points from core operating profit.
- Core operating profit CHF 11,856 million (+10% CER), margin 39.0%; core EPS CHF 10.85 (+9% CER); IFRS net income CHF 7,325 million (–6% in CHF) after CHF 1.0 billion of intangible impairments.
- Pharmaceuticals sales CHF 23,629 million (+6% CER), core margin 53.0%; Xolair was the main growth driver, with Hemlibra, Ocrevus and Phesgo.
- Diagnostics sales CHF 6,735 million (+3% CER), core operating profit CHF 1,180 million (+6%); China sales –15% on pricing reforms, North America +8%.
- Free cash flow CHF 4.2 billion (+58% CER); net debt rose to CHF 22.1 billion after CHF 8.3 billion of dividends.
- M&A: SAGA Dx acquired for USD 408 million (molecular residual disease); PathAI to be acquired for about USD 750 million plus up to USD 300 million (AI pathology); USD 700 million upfront for Nurix's BTK degrader bexobrutideg.
- Risks: Xolair US biosimilars expected from H2 2026; Perjeta biosimilars not expected before 2027 (EU) and 2028 (US); US tariffs raised Diagnostics cost of sales.
- R&D spend +1% CER, focused on giredestrant, divarasib, cevostamab, the obesity/CVRM portfolio and trontinemab.
- Roche Half Year 2026 results webinar (transcript)
- CEO Thomas Schinecker: H1 2026 core operating profit +10% ahead of sales +6% (CER); Diagnostics would have grown 6% without China, and the weak flu season cost about 1% of Group growth.
- Guidance confirmed: mid single digit sales growth, high single digit core EPS growth, higher dividend in CHF; loss-of-exclusivity impact now about 600 million for 2026, less than expected at the start of the year (CFO Alan Hippe).
- Phase III success rate of 80% in 2026; five FDA priority reviews; giredestrant launch expected towards year-end with PDUFA dates on 30 November and 18 December.
- Business development "disciplined": "usually we were not the highest bidder when we won the deals"; recent deals are PathAI, SAGA Diagnostics and Nurix's BTK degrader.
- Pharma CEO Teresa Graham: HER2 franchise peaks around 9 billion (at 2024 exchange rates) in 2026 with a tail of about 4 billion; Ocrevus franchise peak 9 billion by 2029; Vabysmo consensus peak of about 6 billion "very reasonable"; up to 2 billion opportunity for Gazyva in immunology/kidney.
- Obesity: enicepatide (CT-388) phase II showed 26% of patients losing more than 30% of weight at the 24 mg dose; petrelintide phase III go decision taken.
- Diagnostics CEO Matt Sause: Xelios 1 sequencing launched 29 June; target mid single digit growth in 2026 and a return to mid-to-high single digit in 2027; margin broadly stable vs 14.4% in 2025.
- Pipeline value up 93% versus end-2022; about 1.3 billion of R&D efficiencies reallocated to phase III trials; Flatiron now profitable.
- Roche Full Year 2025 results webinar (transcript)
- CEO Thomas Schinecker on FY2025: sales +7% (Pharma +9%, Diagnostics +2%, or +7% without China), core operating profit +13%, core EPS +11%; loss of exclusivity cost about CHF 700 million.
- 2026 guidance: mid single digit sales growth, high single digit core EPS growth, higher dividend; LOE impact expected at about CHF 1 billion (CFO Alan Hippe), tax rate near 20%.
- US government agreement: three-year exemption from tariffs in return for Medicaid rebates on parts of the portfolio, direct-to-patient sales (Xofluza, Tamiflu) and USD 50 billion of US investment over five years.
- Ten NMEs moved into phase III in 2025, "a record"; 19 medicines could launch by end of decade; 66% of late-stage projects with best-in-disease potential.
- Pharma CEO Teresa Graham: on-market portfolio grows until 2028, then stable; "we do not expect a patent cliff"; giredestrant lidERA hazard ratio 0.7 in adjuvant breast cancer; Xolair ~20% growth in 2026 despite a US biosimilar.
- Obesity: CT-388 phase II placebo-adjusted weight loss of 22.5% (efficacy estimand) at 48 weeks; phase III starting Q1 2026.
- Diagnostics CEO Matt Sause: China pricing reform cut China sales 24%; 2026 ambition mid single digit, SBX sequencing a potential CHF 1 billion-plus product.
- Margin stance: expand Group margin in 2026 and keep it at least stable thereafter; R&D broadly flat in 2026, with AI used to speed development and cut cost.
Questions about Roche
What does Roche do?
Roche develops and sells prescription medicines and diagnostic tests and instruments, with a focus on oncology, neurology, immunology, ophthalmology and cardiovascular-metabolic diseases.
What is Roche's revenue?
Group sales were CHF 61,516 million in 2025, up 7% at constant exchange rates; H1 2026 sales were CHF 30,364 million.
How many employees does Roche have?
Roche employed 112,774 people (headcount) at the end of 2025.
Who leads Roche?
Thomas Schinecker is CEO of the Roche Group and Severin Schwan is Chairman; Teresa Graham leads Pharmaceuticals and Matt Sause Diagnostics.
What is Roche's strategy?
Bringing 20 transformative medicines to patients by 2029, a record late-stage pipeline including obesity, and growth platforms in diagnostics such as sequencing and mass spectrometry.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)